

Performance in Initiating and Delivering (PID) Clinical Research
UCLH Performance in Approving and Recruiting to Research
January 2019

Since July 2012, providers of NHS services have been providing data on performance in initiating and delivering clinical research. Data for studies which have received NHS approval (known as Decision to Deliver) in the previous 12 months is submitted quarterly to the National Institute for Health Research (NIHR). Below is a summary of performance submitted by UCLH in Quarter 3 (2018/19) for studies where UCLH was selected as a site over the past year.

Providers are asked to publish details of the length of time taken to approve clinical trials from the point from Date Site Selected to recruitment of the first participant. This period is known as the initiation stage and the NIHR has assigned a benchmark target of 70 days.

Providers also submit information on those Commercially Sponsored Trials, which have closed to recruitment in the year and whether the trial has achieved its anticipated total recruitment target. The period between recruitment of the first participant and reaching the total recruitment target is known as the delivery stage. Each quarter, UCLH will update this information with the most recent studies. The data is correct as of end of December 2018.

For Further information on PID reporting, please visit the NIHR pages at:

<http://www.nihr.ac.uk/policy-and-standards/Performance-in-initiating-and-delivering-research.htm>

Initiating Clinical Research – HRA Approval

	Id	Research Ethics Committee Reference Number	Integrated Research Application System Number	Name of Trial	Date Site Invited	Date Site Selected	HRA Approval Date	Date Site Confirmed By Sponsor	Date Site Confirmed	Date Site Ready To Start	Date of First Participant Recruited	Benchmark Met	Reasons for delay correspond to:
1	134121	17/EE/0474	229785	AdAPT: Adenovirus after Allogeneic Paediatric Transplantation	24/11/2017	21/05/2018	05/01/2018	22/05/2018	30/05/2018	30/05/2018		No	Neither
2	134122	17/EE/0177	220722	BOSTON: Open-label Study of SVD versus VD in patients with RRMM	16/01/2018	29/03/2018	24/07/2017	30/03/2018	09/07/2018	09/07/2018	03/10/2018	No	Neither
3	134123	17/WA/0420	235469	IRL790C003 Phase IIA Parkinson's Dykinesia Study	15/02/2018	12/06/2018	17/01/2018	25/05/2018	22/06/2018	22/06/2018	18/09/2018	No	Sponsor
4	134124	17/YH/0120	208838	DISC - Dupuytren's Interventions Surgery vs Collagenase	17/07/2017	16/05/2018	25/05/2017	05/06/2018	12/06/2018	12/06/2018	13/12/2018	No	Neither
5	134125	17/SC/0615	233555	VIOLETTE	30/01/2018	09/07/2018	05/01/2018	19/07/2018	03/08/2018	06/12/2018	13/12/2018	No	Neither
6	134126	17/LO/1929	233885	Keynote 669	07/11/2017	18/01/2018	19/02/2018	14/02/2018	21/02/2018	08/03/2018		No	Neither

7	134127	17/SS/0082	222441	SoSTART	10/09/2016	21/02/2018	05/10/2017	24/05/2018	31/05/2018	04/06/2018	20/10/2018	No	Neither
8	134128	18/LO/0116	239646	Prexasertib in Recurrent Ovarian Cancer (JTJN)	22/01/2018	24/01/2018	26/03/2018	08/03/2018	06/04/2018	10/04/2018	17/04/2018	No	Sponsor
9	134129	17/EM/0077	206480	LACI-2	24/08/2017	26/04/2018	24/07/2017	01/06/2018	12/06/2018	28/06/2018	17/09/2018	No	Both
10	134130	18/EE/0197	246434	Phase 2 study of the Safety and Efficacy of ADCT-402 on DLBCL Patients	12/06/2018	06/11/2018	10/08/2018	25/10/2018	18/12/2018	18/12/2018	24/12/2018	Yes	
11	134131	18/LO/0226	231912	B7661001 - PF-06647020 in patients with Advanced Solid Tumor	21/09/2017	31/01/2018						No	Sponsor
12	134132	16/SC/0201	202977	A Study of OXB-102, a Gene Therapy, for Parkinsons Disease	07/09/2016	12/02/2018	05/03/2018	19/07/2018	25/07/2018	01/10/2018	01/10/2018	No	Sponsor
13	134133	18/SC/0028	235714	CC-92480 with Dexamethasone in Relapsed & Refractory Multiple Myeloma	17/01/2018	29/01/2018	08/03/2018	31/05/2018	26/07/2018	26/07/2018	19/09/2018	No	Neither
14	134135	18/LO/1598	234799	Feasibility Pilot of a Health Behaviour Change Intervention for TYACS	22/10/2018	14/11/2018	22/10/2018		16/11/2018	16/11/2018		Within 70 days	

15	134136	18/LO/0079	232937	LJPC-401 for iron overload in adults with TDT	09/02/2018	06/07/2018	05/04/2018		11/07/2018	11/07/2018		No	Neither
16	134137	18/LO/0926	241393	RCT: Inflammatory response CO TKA vs Mako TKA	20/10/2017	07/11/2018	07/07/2018		07/11/2018	07/11/2018	07/12/2018	Yes	
17	134138	18/NE/0072	235113	A Study of INCB050465 in Relapsed or Refractory (MCL)	28/03/2017	11/07/2018	18/05/2018		31/08/2018	30/08/2018		No	Neither
18	134139	17/LO/2032	235018	Phase 1/2 Study to Evaluate CORT125281 with Enzalutamide in Patients with Prostate Cancer	27/02/2018	02/03/2018	19/02/2018	12/10/2018	25/10/2018	25/10/2018	19/11/2018	No	NHS Provider
19	134140	18/LO/0448	241283	CALDOSE - 1	19/02/2018	01/05/2018	03/05/2018	30/07/2018	21/08/2018	21/08/2018	17/11/2018	No	Sponsor
20	134141	17/YH/0289	231276	A phase 1/2 study with Acalabrutinib and AZD6738 in high risk CLL	02/01/2018	22/01/2018	18/10/2017	24/05/2018	18/06/2018	18/06/2018	11/09/2018	No	NHS Provider
21	134142	18/EE/0176	236637	DELPHINUS: Daratumumab in paediatric and young adults with ALL/LL	22/12/2017	01/11/2018	13/08/2018		01/11/2018	01/11/2018		Within 70 days	
22	134143	18/LO/0021	236581	EACH	27/03/2018	11/07/2018	26/03/2018		16/07/2018	16/07/2018	19/09/2018	Yes	

23	134144	18/LO/0144	239494	Intra-oral treatment of OLP with Rivelin®-CLO patches	04/12/2017	10/07/2018	17/05/2018	03/08/2018	09/08/2018	09/08/2018	18/09/2018	Yes	
24	134145	18/NE/0210	223922	The MACRO Trial	11/05/2017	24/10/2018	20/07/2018		06/12/2018	06/12/2018		Within 70 days	
25	134146	18/LO/1407	243999	EndoRotor for Refractory BE	05/03/2018	24/10/2018			07/12/2018	11/12/2018		Within 70 days	
26	134147	18/LO/0227	228539	A feasibility study of ACT for people with MND (Phase 1) v1	23/08/2017	11/07/2018	13/03/2018		27/07/2018	27/07/2018	14/09/2018	Yes	
27	134148	17/SS/0105	209066	TEMPO-2	07/03/2018	23/10/2018	27/04/2018		16/11/2018	16/11/2018		Within 70 days	
28	134149	16/EE/0324	203951	Prophylactic and Pre-emptive DLI for myeloid malignancies (PRO-DLI)	19/10/2017	09/03/2018	08/09/2016	17/05/2018	05/06/2018	06/06/2018	18/10/2018	No	Neither
29	134150	18/LO/0696	245087	Phase 2/3 Study of Arimoclomol in IBM	12/12/2016	02/07/2018	18/06/2018		03/08/2018	03/08/2018	31/08/2018	Yes	
30	134151	18/LO/0951	241359	AB-PSP-001	10/04/2018	06/08/2018	19/07/2018	25/09/2018	26/09/2018	26/09/2018	31/10/2018	No	Sponsor

31	134152	18/ES/0042	241253	STARTUP	19/04/2018	22/10/2018	04/07/2018		31/10/2018	31/10/2018		Within 70 days	
32	134153	17/LO/1808	231108	ICON9	19/01/2018	20/06/2018	18/12/2017	19/09/2018	13/09/2018	21/09/2018	04/12/2018	No	Sponsor
33	134154	18/LO/0866	224730	PROHIBIT-ICH	15/12/2017	12/09/2018	26/06/2018	12/10/2018	15/10/2018	15/10/2018		No	Sponsor
34	134155	17/YH/0123	203556	SeluDex	01/02/2018	28/03/2018	12/12/2017	11/04/2018	02/08/2018	02/08/2018		No	NHS Provider
35	134156	17/WS/0081	225638	QUIDS 2	09/05/2018	29/05/2018	15/08/2017	13/06/2018	22/06/2018	22/06/2018	11/07/2018	Yes	
36	134157	18/LO/1148	240856	THRIVEN90	31/07/2018	22/08/2018	31/07/2018		19/09/2018	19/09/2018	25/10/2018	Yes	
37	134158	16/LO/1355	168344	InPACT	31/10/2017	20/06/2018	11/10/2016					No	Neither
38	134159	17/SC/0536	216069	COPELIA	20/10/2017	31/07/2018	04/12/2017	05/09/2018	06/09/2018	06/09/2018	16/10/2018	No	Neither

39	134160	18/SC/0412	250170	Pembro/Placebo+Trastuzumab+C hemo in HER2+ Metastatic Gastric/GEJ	25/06/2018	08/08/2018	19/10/2018		15/11/2018	15/11/2018	20/12/2018	No	Neither
40	134161	18/LO/0789	238844	FLICC II	09/06/2017	14/08/2018	14/08/2018	09/10/2018	09/10/2018	09/10/2018	12/10/2018	Yes	
41	134162	18/LO/0165	224726	POLEM	27/06/2018	16/08/2018	09/05/2018		06/11/2018	06/11/2018		No	NHS Provider
42	134163	18/LO/0030	225990	BARI-OPTIMISE Version 1	28/09/2017	21/09/2018	05/04/2018		25/09/2018	31/07/2018	19/10/2018	Yes	
43	134164	17/LO/0727	217211	Phase 2/3 study in neonates with repeated EEG seizures	27/03/2017	24/09/2018	21/05/2018					No	Sponsor
44	134165	18/LO/0396	238968	NP40126 - A Phase 1B Study Evaluating RO7082859 in Lymphoma	15/03/2018	17/04/2018	16/05/2018		02/08/2018	02/08/2018	24/10/2018	No	Neither
45	134166	17/LO/1273	216265	CheckMate 648	15/08/2017	10/01/2018	30/08/2017	10/01/2018	18/01/2018	18/01/2018	19/06/2018	No	Neither
46	134167	18/EM/0119	244650	Chemotherapy+/- MK-3475 in TKI-resistant EGFR-mutated Tumors in NSCLC	13/02/2018	30/08/2018	06/07/2018	28/08/2018	03/09/2018	03/09/2018		No	Neither

47	134168	17/NI/0203	187583	Short pulse width DBS	08/01/2018	15/03/2018	11/12/2017	22/03/2018	23/03/2018	23/03/2018	02/05/2018	Yes	
48	134169	17/LO/1846	227211	Digital Interventions in Neuro-Rehabilitation (DINR)	18/12/2017	17/01/2018	18/12/2017		26/01/2018	26/01/2018	08/03/2018	Yes	
49	134170	17/LO/1509	232288	MS-STAT2	12/10/2017	18/01/2018	19/01/2018	01/02/2018	02/02/2018	28/03/2018	29/03/2018	Yes	
50	134171	18/NI/0084	239210	Phase 3 trial to evaluate subcutaneous elamipretide injections for PMM	02/07/2018	03/07/2018	26/06/2018	08/10/2018	08/10/2018	08/10/2018	25/10/2018	No	Sponsor
51	134172	18/EM/0079	230431	Vaccination for immune recovery following sepsis: The VACIRISS Trial	12/04/2018	08/08/2018	16/04/2018		09/10/2018	09/10/2018		No	Sponsor
52	134173	17/NE/0061	215780	CONVINCE - Protocol Version 2.1 29th November 2016	18/08/2017	05/04/2018	25/07/2017	15/05/2018	15/05/2018	15/05/2018	20/08/2018	No	Neither
53	134174	17/LO/1433	226791	WATS CDX 810	29/04/2017	01/02/2018	31/01/2018	21/02/2018	23/02/2018	23/02/2018	27/02/2018	Yes	
54	134175	18/LO/0047	235607	ARTISAN-SNM 105-0050	23/01/2018	08/02/2018	22/02/2018	22/02/2018	23/02/2018	23/02/2018	11/04/2018	Yes	

55	134176	17/LO/1972	231646	DSA vs Posterior Approach THA	02/02/2018	21/03/2018	02/01/2018		29/03/2018	29/03/2018	07/07/2018	No	Neither
56	134177	17/LO/0871	215297	MePFAC	03/08/2017	23/05/2018	05/04/2018	23/05/2018	24/05/2018	24/05/2018	29/06/2018	Yes	
57	134178	18/NW/0172	242180	STEP 1 - Semaglutide Treatment Effect in People with obesity	15/12/2017	01/06/2018	17/05/2018	01/06/2018	15/06/2018	15/06/2018	26/06/2018	Yes	
58	134179	18/LO/0370	241124	68Ga-THP-PSMA PET/CT imaging in primary and recurring prostate cancer	08/01/2018	24/05/2018	17/05/2018	13/06/2018	13/06/2018	15/06/2018	25/06/2018	Yes	
59	134180	17/EE/0368	213669	Study into the Reversal of Septic Shock with Landiolol (Beta Blockade)	01/09/2017	21/02/2018	10/11/2017	15/03/2018	20/03/2018	20/03/2018	19/04/2018	Yes	
60	134181	18/LO/0140	238756	SpectraCure P18 Study	09/11/2017	15/05/2018	10/04/2018		19/06/2018	19/06/2018	12/09/2018	No	Neither
61	134702	16/NW/0750	209722	A study to evaluate the acceptability of ZestiVits;	25/09/2017	18/04/2018	09/11/2016	03/05/2018	10/05/2018	11/05/2018	29/05/2018	Yes	
62	134703	18/LO/0150	236497	Interstim Amplitude study	06/10/2017	22/03/2018	27/02/2018	09/04/2018	20/04/2018	20/04/2018	28/06/2018	No	Neither

63	134704	18/LO/0995	244737	Lenvatinib plus Pembrolizumab to Treat Advanced Endometrial Cancer	28/12/2017	21/09/2018	20/09/2018	25/09/2018	24/10/2018	24/10/2018	27/11/2018	Yes	
64	134705	16/EM/0181	201126	TAMARIN	12/07/2017	26/01/2018	02/06/2016	31/10/2017	30/01/2018	13/03/2018	16/07/2018	No	Neither
65	134706	17/SC/0387	208972	MiNivAN trial	20/09/2017	23/03/2018	10/11/2017	08/03/2018	01/05/2018	01/05/2018	11/07/2018	No	Neither
66	134707	18/WM/0082	233489	PKU Lophlex Evaluation	16/04/2018	04/06/2018	16/04/2018					No	Sponsor
67	134708	17/WS/0147	184216	PrecisionPanc	16/11/2017	27/02/2018	05/01/2018	20/02/2018	27/02/2018	01/03/2018	28/06/2018	No	Neither
68	134709	17/NW/0512	221775	PETReA	06/10/2017	18/04/2018	08/11/2017		22/10/2018	22/10/2018		No	NHS Provider
69	134710	16/EM/0322	202096	Tenecteplase in Wake-up Ischaemic Stroke Trial (TWIST)	24/11/2017	21/05/2018	18/08/2017	02/07/2018	17/07/2018	17/07/2018		No	Neither
70	134711	19/LO/0109	257158	GEN-EXTEND	19/12/2018	19/12/2018						Within 70 days	

71	134712	18/WA/0335	240606	PITSTOP	18/09/2018	01/11/2018							Within 70 days	
72	134713	18/EE/0005	232671	Effect on HRCT Endpoints to Glucocorticoid in Pulmonary Sarcoidosis	08/08/2017	13/11/2018	19/07/2018						Within 70 days	
73	134714	18/EM/0112	236871	ALL-RIC	19/07/2018	19/07/2018	12/06/2018	28/09/2018	25/10/2018	25/10/2018			No	Both
74	134715	17/SC/0090	215068	c-TRAK TN	19/10/2017	20/07/2018	22/06/2017		24/08/2018	24/08/2018			No	Neither
75	134716	18/LO/0793	241404	RCT: Mako FA TKA vs Mako MA TKA	18/06/2018	31/07/2018	18/06/2018		07/11/2018	07/11/2018	21/12/2018		No	NHS Provider
76	134717	18/EE/0300	236285	PROMPT	26/09/2018	29/10/2018	19/10/2018						Within 70 days	
77	134718	18/LO/0862	241382	RCT: CO THA vs Mako THA	03/05/2018	23/07/2018	04/07/2018		08/11/2018	08/11/2018	05/12/2018		No	NHS Provider
78	134719	17/EE/0040	222216	ENCIRCLE Emergency Cerclage in Twins at Imminent Risk of preterm birth	11/09/2017	02/02/2018	02/03/2017		15/02/2018	15/02/2018			No	Neither

79	134720	17/LO/1678	211950	Lateral Flow Assay and Reader for Malaria Detection version 1.0	12/11/2017	29/05/2018	08/11/2017		04/06/2018	04/06/2018	01/11/2018	No	Neither
80	134721	18/LO/1141	241087	Minifast - Obs	18/01/2018	25/07/2018	24/07/2018		09/08/2018	09/08/2018		No	Sponsor
81	134722	18/SC/0250	243935	Mental health in children with epilepsy trial (MICE)	24/04/2018	05/10/2018	21/05/2018	23/11/2018	24/10/2018	22/11/2018	03/12/2018	Within 70 days	
82	134723	18/YH/0329	236786	PEACOC	30/07/2018	20/11/2018	16/10/2018	11/12/2018	21/12/2018			Within 70 days	
83	134724	18/EM/0364	254750	4433: NNC0174-0833 for weight management	12/12/2018	12/12/2018						Within 70 days	
84	134725	18/LO/2136	251414	BN40423 Generation HD 1	11/12/2018	11/12/2018						Within 70 days	
85	134726	18/EE/0352	238983	Biomarker-Directed, Pembrolizumab Based Combination Therapy for Advanced NSCLC	12/10/2018	22/11/2018						Within 70 days	

Delivering Clinical Research

Id	Research Ethics Committee Reference Number	Integrated Research Application System Number	Name of Trial	Target Number of Patients Agreed?	Minimum Number Of Patients Agreed (Enter Same In Both If Only One Number)	Maximum Number Of Patients Agreed (Enter Same In Both If Only One Number)	Target Date To Recruit Patients Agreed?	Date Agreed to recruit target number of patients	Total Number Of Patients Recruited At The Agreed Target Date	Date That The Trial Closed To Recruitment	Total Number Of Study Participants Recruited	Reason For Closure Of Trial	Comments
33741	17/EE/0291	203703	Phase III trial- pembrolizumab or brentuximab vedotin- Hodgkin Lymphoma	Number Agreed	2	2	Date Agreed	28/02/2018	2	13/08/2018	3	Recruitment Finished	Recruitment met
33742	14/YH/1056	147421	NCRN - 3215 masitinib, dexamethasone and gemmicitabine in peripheral T cell lymphoma	Number Agreed	5	5	Date Agreed	03/03/2017	5	30/05/2018	2	Recruitment Finished	Recruitment met

33743	14/SC/1366	135118	NCRN - 3131: EPOCH TheraSphere in Metastatic Colorectal Carcinoma of the Liver (TS102)	Number Agreed	6	6	Date Agreed	18/05/2015	6	12/10/2018	10	Recruitment Finished	Recruitment met
33744	18/NW/017 2	242180	STEP 1 - Semaglutide Treatment Effect in People with obesity	Number Agreed	20	20	Date Agreed	05/11/2018	15	19/10/2018	15	Recruitment Finished	Planned Recruitment Closure
33745	16/LO/2157	217001	Retrophin	Number Agreed	4	4	Date Agreed	20/12/2017	0	30/12/2018	0	Recruitment Finished	Recruitment target fulfilled by other sites. Study terminated by sponsor

33746	14/NE/1063	144094	GAST 3559 (Ulcerative Colitis)	Number Agreed	4	4	Date Agreed	30/03/2017	4	29/08/2018	1	Recruitment Finished	
33747	15/LO/1079	177212	A safety and efficacy study of Multistem Cell Therapy for ARDS	Number Agreed	4	6	Date Agreed	01/09/2018	4	19/09/2018	4	Recruitment Finished	Met the recruitment target as planned
33748	17/WM/030 4	230388	BENEFIT 15	Not Available / Not Agreed			Date Agreed	09/12/2017	1	14/03/2018	1	Recruitment Finished	Study completed

33749	17/LO/0096	220205	SUSTAIN (205MS305)	Number Agreed	2	2	Date Agreed	29/06/2018	0	15/03/2018	0	Withdrawn By Sponsor	Early termination - study has been terminated early by sponsors.
33750	17/NS/0107	234519	Real World Outcomes of Patients with mCRC	Number Agreed	200	200	Date Agreed	29/05/2018	108	31/07/2018	108	Recruitment Finished	Revised and agreed target with Sponsors
33751	17/LO/1920	235022	Phase 3 Open-label with BIVV009 in Subjects with CAgD	Number Agreed	2	2	Date Agreed	31/12/2018	2	15/11/2018	2	Recruitment Finished	Closed to Recruitment , in Follow up

33752	17/SW/026 4	231574	Neuf Study 20160441	Number Agreed	2	2	Date Agreed	17/07/2018	2	26/04/2018	3	Recruitment Finished	Recruitment Met
33753	17/SC/0055	219468	AIN457 Paed	Number Agreed	2	2	Date Agreed	01/10/2018	2	10/10/2018	2	Withdrawn By Sponsor	Sponsor closed to recruitment
33754	17/EM/018 3	220783	Effect of mepolizumab in severe bilateral nasal polyps	Number Agreed	4	4	Date Agreed	11/05/2018	4	31/08/2018	4	Recruitment Finished	Patient numbers met

33755	15/SC/0666	187031	NEUR 4805	Number Agreed	10	10	Date Agreed	31/10/2018	7	05/11/2018	8	Recruitment Finished	n/a
33756	16/LO/1755	209250	Revita-2	Number Agreed	15	15	Date Agreed	09/06/2017	15	09/11/2018	15	Recruitment Finished	Recruitment was terminated by the sponsor as the sponsor had collected enough data for the study.
33757	14/LO/1672	158949	CANC - 3716 POLO1 Olaparib in gBRCA Mutated Metastatic Pancreatic Cancer	Number Agreed	1	1	Date Agreed	30/09/2017	1	15/08/2018	1	Recruitment Finished	Closed to Recruitment as Planned or Later

33758	17/EE/0038	217456	RATRPstudy	Range Agreed	1	3	Date Agreed	25/09/2018	0	18/05/2018	0	Recruitment Finished	Reached global recruitment target
33759	14/WS/111 3	153352	CHIL3593 (P11-292)	Number Agreed	25	25	Date Agreed	01/12/2015	25	01/02/2018	0	Recruitment Finished	Global Competitive Recruitment Target Met
33760	17/NS/0077	218279	BLAST OSA study version 01A multicenter, prospective, open-label, non-randomised	Number Agreed	3	3	Date Agreed	31/12/2017	3	05/05/2018	0	Recruitment Finished	Recruitment ended

33761	16/LO/0581	194313	CANC 5246	Not Available / Not Agreed			Not Available / Not Agreed	N/A	N/A	11/10/2018	4	Recruitment Finished	Recruitment Met
33762	15/SS/0150	176768	CANC - 4974	Number Agreed	6	6	Date Agreed	30/06/2017	6	27/11/2018	1	Withdrawn By Sponsor	Sponsors decision: trial limitations and operationally challenging
33763	13/NW/069 7	137274	NCRN - 2352 PISARRO	Range Agreed	3	5	Date Agreed	31/12/2018	3	03/05/2018	0	Withdrawn By Host	Site withdrew from this study

33764	16/EM/0173	184117	PM01183 in Selected Advanced Solid Tumors	Number Agreed	10	10	Date Agreed	30/08/2018	10	17/12/2018	13	Recruitment Finished	Reached recruitment total
33765	18/ES/0045	244263	Observational Study of Pegvaliase-Naïve Adults with Phenylketonuria	Number Agreed	10	10	Date Agreed	12/06/2021	0	09/01/2018	245	Recruitment Finished	NA
33766	17/EE/0264	228153	Efficacy of Durvalumab/Tremelimumab with SoC chemo in metastatic NSCLC	Number Agreed	8	8	Date Agreed	30/11/2018	8	04/08/2018	1	Recruitment Finished	Recruitment met

33767	16/WM/043 9	211177	EndoStim CS-100 FDA study	Number Agreed	8	8	Date Agreed	13/02/2017	8	01/06/2018	0	Recruitment Finished	Closed to Recruitment as Planned or Later
33768	17/LO/0618	223878	IMvigor130	Number Agreed	4	4	Date Agreed	30/03/2018	4	25/06/2018	3	Recruitment Finished	Global Competitive Recruitment Target Met
33769	16/EM/032 4	204032	DEME 5472	Number Agreed	8	8	Date Agreed	30/03/2018	8	14/08/2018	2	Recruitment Finished	Completed recruitment

33770	16/NW/030 5	201856	Ipsen223	Number Agreed	4	4	Date Agreed	31/12/2018	2	03/10/2018	2	Recruitment Finished	Unable to reach recruitment target
33771	16/LO/0675	147355	CANC 5613	Number Agreed	3	3	Date Agreed	30/08/2018	3	03/07/2018	0	Recruitment Finished	Lack of Equipoise
33772	17/WS/005 9	211178	IRX-2 2015A	Number Agreed	6	6	Date Agreed	01/06/2018	6	19/01/2018	0	Recruitment Finished	Sufficient data was gathered globally from 100 patients randomized. Global Target was originally 200 patients. The study was overpowered.

33773	17/LO/0284	221453	GSK3008348 in IPF	Number Agreed	7	7	Date Agreed	28/02/2018	7	01/06/2018	1	Recruitment Finished	Primary end point achieved
33774	16/EM/043 9	199809	NOVELTY	Not Available / Not Agreed			Not Available / Not Agreed	N/A	N/A	26/03/2018	0	Recruitment Finished	Global Competitive Recruitment Target Met
33775	17/LO/0797	220423	ABRE Study	Number Agreed	9	9	Date Agreed	30/12/2018	9	29/11/2018	8	Recruitment Finished	Closed to Recruitment as Planned or Later

33776	17/LO/0089	219229	GS-US-342-4062	Not Available / Not Agreed			Not Available / Not Agreed	N/A	N/A	31/01/2018	0	Recruitment Finished	Closed to Recruitment as Planned or Later
33777	17/EE/0079	220827	CL010_168	Not Available / Not Agreed			Not Available / Not Agreed	N/A	N/A	01/06/2018	2	Recruitment Finished	Numbers achieved
33778	17/NW/0175	222859	PRTX-100 in ITP	Number Agreed	2	2	Date Agreed	15/11/2017	2	17/05/2018	2	Recruitment Finished	Completed

33779	16/EM/043 6	213166	AQ-03	Number Agreed	2	3	Date Agreed	29/10/2018	7	25/05/2018	3	Recruitment Finished	Recruitment completed
33780	17/EM/042 5	236800	Retrospective review of current treatment pathways for MF in the UK	Not Available / Not Agreed			Not Available / Not Agreed	N/A	N/A	12/07/2018	0	Recruitment Finished	Closed to Recruitment as Planned or Later
33781	17/LO/1656	229212	CO39722 - Cobimetinib and atezolizumab v's pembrolizumab in melanoma	Number Agreed	3	3	Date Agreed	30/10/2018	3	07/11/2018	1	Recruitment Finished	Closed to Recruitment as Planned or Later

33782	15/NE/0167	171524	CANC - 3527 Ixazomib in Multiple Myeloma	Number Agreed	1	1	Date Agreed	30/07/2017	3	13/09/2018	0	Recruitment Finished	Global Competitive Recruitment Target Met
-------	------------	--------	------------------------------------------	---------------	---	---	-------------	------------	---	------------	---	----------------------	-------------------------------------------